Low levels of the key B cell activation marker, HLA-DR, in COVID-19 hospitalized cases are associated with disease severity, dexamethasone treatment, and circulating IL-6 levels.
Immunol Res
; 70(5): 714-719, 2022 10.
Article
in English
| MEDLINE | ID: covidwho-1942991
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Interleukin-6
/
COVID-19 Drug Treatment
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
Immunol Res
Journal subject:
Allergy and Immunology
Year:
2022
Document Type:
Article
Affiliation country:
S12026-022-09269-w
Similar
MEDLINE
...
LILACS
LIS